Last reviewed · How we verify

insulin glulisin / insulin detemir

Sanofi · Phase 3 active Small molecule

insulin glulisin / insulin detemir is a insulin analog Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Type 1 diabetes, Type 2 diabetes.

Insulin glulisine and insulin detemir work together to lower blood sugar levels by stimulating the uptake of glucose by cells.

Insulin glulisine and insulin detemir work together to lower blood sugar levels by stimulating the uptake of glucose by cells. Used for Type 1 diabetes, Type 2 diabetes.

At a glance

Generic nameinsulin glulisin / insulin detemir
SponsorSanofi
Drug classinsulin analog
Targetinsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Insulin glulisine is a rapid-acting insulin analog that starts working within 15 minutes of injection, while insulin detemir is a long-acting insulin analog that provides a steady level of insulin in the body for up to 24 hours. Together, they help to control blood sugar levels throughout the day and night.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about insulin glulisin / insulin detemir

What is insulin glulisin / insulin detemir?

insulin glulisin / insulin detemir is a insulin analog drug developed by Sanofi, indicated for Type 1 diabetes, Type 2 diabetes.

How does insulin glulisin / insulin detemir work?

Insulin glulisine and insulin detemir work together to lower blood sugar levels by stimulating the uptake of glucose by cells.

What is insulin glulisin / insulin detemir used for?

insulin glulisin / insulin detemir is indicated for Type 1 diabetes, Type 2 diabetes.

Who makes insulin glulisin / insulin detemir?

insulin glulisin / insulin detemir is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is insulin glulisin / insulin detemir in?

insulin glulisin / insulin detemir belongs to the insulin analog class. See all insulin analog drugs at /class/insulin-analog.

What development phase is insulin glulisin / insulin detemir in?

insulin glulisin / insulin detemir is in Phase 3.

What are the side effects of insulin glulisin / insulin detemir?

Common side effects of insulin glulisin / insulin detemir include Hypoglycemia, Weight gain, Allergic reactions.

What does insulin glulisin / insulin detemir target?

insulin glulisin / insulin detemir targets insulin receptor and is a insulin analog.

Related